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Abstract
Background: Although the sequencing landscape is rapidly evolving and sequencing costs are continuously
decreasing, whole genome sequencing is still too expensive for use on a routine basis. Targeted resequencing
of only the regions of interest decreases both costs and the complexity of the downstream data-analysis.
Various target enrichment strategies are available, but none of them obtain the degree of coverage uniformity, flexibility
and specificity of PCR-based enrichment. On the other hand, the biggest limitation of target enrichment by PCR is the
need to design large numbers of partially overlapping assays to cover the target.
Results: To overcome the aforementioned hurdles, we have developed primerXL, a state-of-the-art PCR primer design
pipeline for targeted resequencing. It uses an optimized design criteria relaxation cascade and a thorough
downstream in silico evaluation process to generate high quality singleplex PCR assays, reducing the need for
amplicon normalization, and outperforming other target enrichment strategies and similar primer design tools
when considering assay quality, coverage uniformity and target coverage. Results of four different sequencing
projects with 2348 amplicons in total covering 470 kb are presented. PrimerXL can be accessed at www.primerxl.org.
Conclusion: PrimerXL is an state-of-the-art, easy to use primer design webtool capable of generating high-quality
targeted resequencing assays. The workflow is fully customizable to suit every researchers’ needs, while an innovative
relaxation cascade ensures maximal target coverage.
Keywords: Primer design, Targeted resequencing, Variant confirmation next generation sequencing, Sanger sequencing,
PCR assay
Background
Massively parallel sequencing has opened the path
towards personalized genomics but the current sequen-
cing cost and limitations in data-analysis impede the wide
use of whole-genome sequencing in a clinical context.
However, by focusing the power of this new technology
on a region of interest through specific target enrichment
and pooling multiple samples in one sequencing run, the
sequencing cost can be reduced dramatically [1, 2]. Differ-
ent target enrichment strategies have emerged, each with
their own benefits and limitations. Enrichment through
hybridization, either array- or solution-based [2–5], is
capable of capturing larger target regions but lacks the
flexibility of PCR-based approaches in the context of spe-
cificity (when pseudogenes are known for the gene of
interest), regional GC content and gene panel contents.
The latter is mainly the case for array-based hybridization
enrichment, since addition of targets to an existing panel
requires the redesign of the array.. In addition, on-array
target enrichment requires specialized instruments and
relatively large amounts of DNA. Although enrichment by
PCR seems to outperform hybridization enrichment strat-
egies when looking at specificity and coverage uniformity,
this strategy is less frequently used thus far due to the fact
that performing many PCRs in parallel may not be
straightforward and that multiple assays need to be
designed to cover the complete region of interest [2, 5].
More recent high-throughput PCR strategies, such as
micro-droplet PCR by Raindance [6], nanoliter SmartChip
reactions by WaferGen Biosystems and Access arrays by
Fluidigm, could bring PCR enrichment into the
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mainstream. The large number of parallel small-volume
reactions in these new platforms substantially reduces the
turnaround time, cost and the required amount of input
DNA. However, a bottleneck remains, i.e. the design of a
large number of PCR assays. While various primer design
software packages are available, most are not suited for
amplicon generation in the context of targeted resequen-
cing of entire genes. ExonPrimer [7] expects the input of a
cDNA and matching genomic sequence to extract intron-
exon boundaries. Customization is limited and some
essential downstream primer pair evaluations, such as spe-
cificity and secondary structure assessment, are lacking.
The Optimus Primer pipeline [8] is more user friendly,
accepts both official gene symbols and chromosomal
regions as input and is able to perform up to four design
criteria relaxation steps to maximize target coverage. The
presence of secondary structures in primer annealing sites
is not evaluated and the process of splitting up larger
exons or regions in smaller fragments to be processed in
parallel, limits both the possibility to optimize target
coverage (i.e. minimizing amplicon overlap and near-
target coverage) and to reduce the number of amplicons.
To address these shortcomings, we have developed pri-
merXL, a state-of-the-art high-throughput primer design
pipeline for massively parallel targeted resequencing. It
employs an optimized design parameter relaxation cas-
cade and multiple primer pair quality control analyses,
generating high quality and robust singleplex PCR assays
resulting in uniform sequencing coverage. In addition, an
accompanying straightforward and easy to use web tool
has been developed for users to fully customize their
designs, starting with a gene symbol, transcript ID or
chromosomal region as input. PrimerXL is available at [9].
Implementation
PrimerXL workflow
PrimerXL is a fully automated, modular pipeline, making
it easy to add, remove or change features. Its heart con-
sists of a copy of the Ensembl core and variation data-
bases [10] for a number of selected species and custom
MySQL tables for storage of design requests and results.
The power of primerXL lies in the fact that it combines
the proven primer3 primer design engine [11] with opti-
mized parameter relaxation and a thorough downstream
in silico assay evaluation. PrimerXL generates high qual-
ity primer pairs, omitting the need for laborious wet-lab
assay testing and optimization while covering close to
100% of the target region.
The workflow of the primerXL pipeline is simple and
completely customizable. Once a design request has
been submitted by way of a chromosomal region, gene
symbol or transcript ID, primerXL starts by retrieving all
relevant DNA sequences. In case a gene symbol is sup-
plied, the input sequence will consist of the unique
coding sequences of all corresponding transcripts. Next,
features such as single nucleotide polymorphisms (SNP)
and secondary structures, known to have a negative
effect on amplification efficiency [12–14] are masked in
the DNA sequences based on data of the Ensembl vari-
ation database [10] and results of a UNAfold analysis
[15], respectively. Excluding SNPs and secondary struc-
tures from primer annealing sites is essential since these
can hamper proper hybridization of a primer to its target
sequence. This may result in allelic drop out and re-
duced amplification. In order to increase the throughput
of the pipeline, parallel child processes are created for
each exon or chromosomal region to perform the primer
design and the downstream in silico evaluation for the
corresponding target region. Tasks executed by the child
process are indicated in blue and green in Fig. 1.
In order to cover putative mutations in donor and
acceptor splice sites and to accommodate lower sequen-
cing quality at the start of a read – especially in the case
of Sanger sequencing – primerXL offers the possibility
to include 5′ and 3′ intronic regions in the target to be
sequenced. As a consequence, when describing our
results, amplicon sequences will be divided in three
parts. The exonic on-target region is the part of an
amplicon covering the actual region of interest, being
the exon or the chromosomal location of interest. The
extra-included 3′ and 5′ intronic regions are referred to
as intronic on-target, while the rest of the amplicon is
defined as intronic near-target (Fig. 2g). Maximizing tar-
get coverage while minimizing the number of required
amplicons is achieved by means of an optimized relax-
ation cascade (indicated in blue in Fig. 1). First, using
the parameters set by the user, primerXL will try to span
the entire fragment under consideration using a single
amplicon. If this fails (for example because the size of
the fragment is exceeding the maximum set amplicon
length), design settings will be relaxed until a targeted
resequencing assay is successfully generated or all relax-
ation options have been exhausted. The default relaxation
cascade comprises – in order of their execution – allowing
SNPs in primer annealing sites except for a predefined
region on the primer 3′ end [12, 13], increasing the GC
clamp size (i.e. the number of G/C nucleotides in the last
5 base pairs on the 3′ end of a primer) incrementally to its
maximum [16], tolerating small secondary structures in
annealing sites, stepwise (100 bp per step) increasing
amplicon length to a maximum of 1.5 times the original
upper length limit, enlarging the allowed annealing
temperature range (stepwise by 0.5 °C with a maximum
range of 5 °C) and finally relaxing specificity analysis by
reducing the maximum number of mismatches allowed in
potential annealing sites. When all possible relaxation
options and their combinations have been considered
without the successful generation of an assay, primerXL
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will redefine its target. This process depends on the size of
the fragment. If the size of the fragment is larger than the
minimum set amplicon length, primerXL will define a re-
gion on the 3′ end of the fragment as the new target, reset
the relaxation cascade and attempt to find an assay ampli-
fying only this piece of the fragment. However, if the frag-
ment is already smaller than the minimum amplicon
length, primerXL will shift its focus to the 5′ end of the
fragment (i.e. the part of the fragment that remained after
target-redefinition will now become the fragment of inter-
est) and restart the whole procedure. The design process
ends when the initial fragment has been covered com-
pletely or when the size of the 5′ end of the fragment from
the previous design step is smaller than the minimum
amplicon length and no assays can be found to cover it. In
addition to fragmenting large regions in this way, pri-
merXL can also dynamically adjust the amplicon size
range for smaller exons, thus maximizing the target size
that can be sequenced in one run by limiting the size of
undesired near-target sequences.
Three types of downstream in silico assay evaluation
procedures are incorporated in primerXL. The first type
assesses the presence of SNPs in primer annealing sites.
In the most stringent setting, assays harboring SNPs in
primer annealing sites are filtered out by masking them
by means of Primer3 sequence quality scores. If SNP re-
laxation is enabled, this feature ignores the quality scores
during Primer3 design, but allows the use of the scores
after design to annotate SNP presence for each assay in-
dividually. This can be used to guarantee that no SNPs
are present in a predefined number of bases at the 3′
end of a primer. This number can be set by the user but
we observed that mismatches are well tolerated, except
in the last five base pairs on the 3′ end of a primer [17].
The location of secondary structures in primer annealing
sites is assessed in the same way as for SNPs, by taking
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Fig. 1 PrimerXL targeted resequencing PCR design pipeline. Schematic representation of the primerXL pipeline functionality. Tasks performed by
the parent process are marked in yellow, tasks executed by the child processes in green and blue. The design criteria relaxation cascade is shown
in blue. Following retrieval of the sequence of interest (and adjustment of the amplicon size range for small regions), SNPs and secondary
structures are masked. Next Primer3-based primer design is initiated and a SNP- and secondary structure analysis is performed on each resulting assay
to remove assays harboring these features in their primer annealing sites. If a successful primer pair remains after specificity assessment, the next target
region is processed or the design is terminated. On the other hand, if no successful assays remain, design parameters are relaxed (specificity-, SNP- and
secondary structure analysis stringency, GC content, amplicon length,…) and primer design is attempted once again. If all parameters have already
been relaxed to their fullest extent without the generation of a successful primer pair, the design process is terminated
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into account sequence quality scores in Primer3. However,
since secondary structures can vary between the final
amplicon and the original template in its sequence con-
text, we cannot rely on these quality scores solely. Both in
the most stringent and relaxed mode, it is important to re-
analyze the secondary structure content of the amplicon
by way of a second type of post-design evaluation to en-
sure that primer annealing sites are free of secondary
structures. The final downstream in silico assay evaluation
uses a local Bowtie implementation to determine the spe-
cificity of the primer pair by aligning the forward and re-
verse primer sequences against the reference genome, in
combination with a user-defined maximum allowed num-
ber of mismatches [18]. By using a higher mismatch num-
ber, potential non-specific annealing sites harboring
mismatches will be returned along with the perfect match-
ing regions. This allows to discard assays with a non-
specific amplification potential by accepting primer pairs
that only return the perfect hits, even when using
higher mismatch numbers to screen for potential non-
specific amplification. Together, these three detailed
downstream in silico assay evaluations result in high
quality singleplex primer pairs. Due to the modular na-
ture of primerXL, additional evaluations can be added.
User interface
To allow users to easily customize and submit primer
design jobs, a user-friendly web-interface was created.
PrimerXL is available for Homo sapiens, Mus musculus,
Rattus norvegicus, Oryza sativa, Arabidopsis thaliana,
Equus caballus, Zea mays, Triticum aestivum, Bos Taurus,
Sus scrofa and Danio rerio. Additional organisms can be
added upon request. Following specification of the project
name and species selection, the user will be requested to
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Fig. 2 Amplicon and sequencing statistics. Graphical representation of the amplicon and sequencing statistics of four sequencing projects. a Target
coverage efficiency, b Distribution of the amplicon sequence, c Schematic displaying the different on- and off-target portions of an amplicon,
d Cumulative distribution of the amplicon length, e Cumulative distribution of the Cq values (amplicons of Project 2 were tested by regular
PCR), f Cumulative distribution of the end-point fluorescence and g Cumulative distribution of the sequencing coverage
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choose the template for which tiling assays should be
designed. The required identifier (gene, transcript or
chromosomal location) depends on the chosen tem-
plate. For a cDNA template, a gene or transcript identi-
fier will be asked; for a genomic DNA (gDNA) template,
an option to enter a chromosomal location is available. If
a supplied identifier results in multiple hits when querying
the database, matching suggestions will be shown to the
user (gene and/or transcript identifiers depending on the
template) in order to select the preferred one. All user
adjustable primerXL settings, including the parameters of
the third-party software packages such as primer3, UNA-
Fold and Bowtie, are available online. Optimized – but
customizable – default settings have been predefined for
Sanger sequencing, Roche 454 and Illumina resequencing.
After submission, the design request is stored in a data-
base and executed on the primerXL server. Currently, no
locally installable version of the tool is available. Once pri-
mer design has been completed, results are emailed to the
user and can be viewed online. Non-commercial access to
primerXL is available after registration and the number of
targeted resequencing requests has been limited to one
per user per month. PrimerXL is available at [9].
Results
In our department, primerXL has been extensively used
for targeted re-sequencing. One of the first projects
entailed the Roche 454 sequencing of 15 genes involved
in hereditary deafness (Project 1 using primerXL v0.8
(see Table 1) – 83 Kb) and generated 625 amplicons
targeting 91.76% of the coding sequences of all corre-
sponding transcript variants [19]. When running the
same genes using the latest version of primerXL (v1.0),
target coverage increased to 95.7%. Sixty five percent of
the amplicon sequence, 185 Kb in total, was on target
with over 90% of the amplicons with a length between
200 and 350 bp, well suited – at that time – for Roche
454-FLX sequencing. Upon assay evaluation using qPCR
(mean Cq value: 28.9 ± 2.76), 17 assays failed (2.7%) due
to no or limited amplification (Cq > 35) while another
40 amplicons were finally not included in the sequencing
for being too long (> 500 bp). End-point fluorescence
uniformity was high (93.3% within 2-fold difference of
the mean), meaning that no concentration normalization
is needed for these amplicons as they will result in a
uniform coverage [20]. This was confirmed upon
sequencing on a Roche 454-FLX instrument (3 samples
on a conventional run) with 70% of the targeted bases
within 2-fold above and 2-fold under the mean coverage
of 240 reads/base (89.2% within 5-fold above and 5-fold
under the mean coverage). None of the amplicon associ-
ated parameters – such as GC content, overall Gibbs
free energy and length – were correlated with assay
performance or sequencing coverage (Additional file 1:
Figure S1A-C). However, primer pair specificity and sec-
ondary structures in primer annealing sites were shown
to have an effect on sequencing coverage. Assays harbor-
ing secondary structures in at least on of its primer an-
nealing sites tend to result in lower sequencing coverage
(Additional file 1: Figure S1D). Similarly, sequencing cover-
age is significantly influenced by the assay specificity level,
calculated as described in previous work [21]. This is to be
expected as lower specificity means that the non-specific
products take away a fraction of the sequencing capacity,
leaving fewer reads for the amplicon of interest (Additional
file 1: Figure S1E). A setup, similar to the one applied for
project 1, was used for targeting 24 genes (Project 2 using
primerXL v1.0–157 Kb) used in a diagnostic setting where
sequencing is planned by Roche 454 technology. The
primer design resulted in 723 amplicons covering 96.1%
of the target with high amplicon length uniformity
(84.5% between 300 and 450 bp). Currently, 638 ampli-
cons have been tested by PCR with a (strict definition
of ) success rate of 87% (79 non-specific assays and 6
assays with no amplification). Comparison between
these two projects (Project 1 and 2) clearly shows the
added value of the relaxation. Whereas 91.76% target
coverage was achieved by manually relaxing the design
settings, implementation of automatic relaxation in-
creased this percentage to 96.1%. Another approach
was used in a third project sequencing 23 Leber con-
genital amaurosis (LCA) and Retinitis Pigmentosa (RP)
genes (Project 3 using primerXL v0.9–132 Kb) on the
Illumina GAIIx system [22]. Since dynamic optimization
was not implemented yet in version 0.9, two primer design
rounds with different amplicon sizes (400 bp and 600 bp)
were performed from which amplicons were selected to
optimally cover all exonic sequences of the corresponding
RefSeq transcripts. Both design approaches gave a 96%
target coverage, the 600 bp designs showed a higher in-
tronic near-target percentage as expected (35% versus 24%
for the 400 bp designs). In total, 375 amplicons covering
the RefSeq transcripts of 16 LCA genes (67 Kb) were
ligated and fragmented prior to sequencing. Of these
amplicons, 96.5% had a Cq below 35 (mean Cq value:
26.4 ± 3.01) while 99.2% had an end-point fluorescence
within 2-fold difference of the mean. Coverage analysis of
12 samples sequenced on an Illumina GAIIx instrument
Table 1 PrimerXL feature overview in function of pipeline version
Version Relaxation cascade Dynamic target adjustment
0.8
0.9 V
1.0 V V
Differences in primerXL features between the various versions used in this
study. The term “dynamic target adjustment” refers to the ability of primerXL
to automatically adjust the amplicon size range for smaller exons, thus
reducing the amount of intronic near-target sequence
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(1 lane) indicated that 59% of the targeted bases are within
2-fold above and 2-fold under the mean coverage of the
mean coverage of 1232 reads/base (88.6% within 5-fold
above and 5-fold under the mean coverage). With respect
to coverage analysis, similar conclusions as to the ones for
project 1 can be drawn. Assay specificity and secondary
structures in primer annealing sites seem to have an effect
on sequencing coverage, while no impact can be observed
for amplicon GC content, overall Gibbs free energy and
amplicon length (Additional file 2: Figure S2A-E). The
best results were obtained in the fourth project sequen-
cing 558 exons (Project 4 using primerXL v1.0–98 Kb).
Nearly 98.9% of the targets were covered using 625
amplicons of which only 8 (1.2%) resulted in a Cq
higher than 35 (mean Cq value: 24.3 ± 1.88). Although
no sequencing data are available yet, 96.8% of the as-
says showed an end-point fluorescence within 1.5 times
the mean. The results from these four projects are sum-
marized in Table 2 and Fig. 2.
All aforementioned experiments were performed with
high-quality DNA, allowing longer amplicon lengths.
For formalin-fixed paraffin embedded (FFPE) tissue sam-
ples resulting in fragmented DNA, assays generating
shorter amplicons are commonly applied. While the
degree of fragmentation is dependent on the age of the
sample and the type and duration of fixation, in general
assays shorter than 300 nucleotides are recommended.
To determine how primerXL copes with shorter amplicon
size ranges, we designed assays for 31 genes – i.e. the 15
deafness genes from project 1 and 16 LCA genes included
in project 3 – using 80–200, 200–300 and 80–300 base-
pair size ranges. Results depicted in Additional file 3:
Figure S3, show that the coverage for these size ranges is
significantly lower than what could be obtained with lon-
ger products in the aforementioned projects. Seeing that
the failure rate for longer exons (larger than 1 kb) of
27.5% (11/40 failed exons) is larger than the failure rate
for shorter exons (3.56% or 24/674 exons), this could
partly be explained by the hard-coded three-day design
limit embedded in primerXL combined with the more
limited design space inherent with shorter amplicon sizes.
Indeed, the more stringent design space further increases
the already longer design time associated with larger
exons, pushing them toward the design wall-time resulting
in an increased number of them to end prematurely with-
out successful assays. To circumvent this, users can split
up larger exons manually although this will most likely
result in suboptimal tiling. This could be confirmed by
splitting up the exons larger than 1 kb that failed to gener-
ate assays using the 80–300 basepair setup, into fragments
of approximately 500 bp. Using this approach, the pipeline
was able to cover 67.28% of these fragments bringing the
total coverage for the 31 genes up to 90.12%. Shorter
amplicon assay design is likely also to negatively impact
the specificity of the design (given the higher design
constraint and smaller design space) and as such make
designs for genes with pseudogenes somewhat more
challenging.
To assess primerXL performance in comparison to
other primer design tools, targeted resequencing assays
were designed for five randomly selected genes (SACS,
SETX, APTX, ANO10 and CYP27A1) using three different
tools (primerXL, Illumina DesignStudio and Optimus
Primer). Although differences in target region can be ob-
served among the tools – DesignStudio uses the Illumina
UCSC iGenomes (hg19), primerXL targets the exons of all
known transcript variants of the gene of interest, and
Optimus Primer is based on NCBI reference transcripts
(RefSeqs) – comparisons can be made by taking into ac-
count the corresponding target size when calculating the
different parameter percentage values. Here we looked at
the percentage of the target each tool was able to cover
using targeted resequencing assays, as well as the percent-
age of the total amplicon sequence that was either on- or
near-target. In addition, in silico assay evaluations were
performed to assess how each primer design tool copes
with features known to affect PCR assay performance
such as the presence of SNPs and secondary structures in
primer annealing sites [14]. Design settings between the
three tools were kept identical where possible. The ampli-
con size range for both primerXL and Optimus Primer
was set at 350 to 450 bp. In contrast to the automatic
relaxation cascade in primerXL, relaxed parameters had
to be set manually in Optimus Primer (1st relaxation:
allow SNPs in primer annealing sites; 2nd relaxation: mask
SNPs and increase amplicon size range to 450–550 bp;
3rd relaxation: don’t mask SNPs and increase amplicon
size range to 450–550 bp). The Illumina DesignStudio
does not allow customization of the amplicon length, nor
the adjustment of the relaxation cascade. When looking at
the targeted resequencing assays designed by the three
primer design pipelines, it is clear that primerXL is able to
cover more of its target (98.6% for primerXL versus 92.9%
for Optimus Primer and 95.9% for DesignStudio – Fig. 3a),
while maintaining a high on-target percentage (83.2%)
(Fig. 3b). Although DesignStudio shows the highest on-
target ratio (88.5%), the percentage of amplicons harbor-
ing SNPs in at least one primer annealing site is more than
twice as high compared to primerXL, indicating that the
primerXL assays are likely to be more robust and insensi-
tive to natural sequence variation (Fig. 3c). The low on-
target percentage for Optimus Primer can be attributed to
the fact that all assays were designed using the third relax-
ation setting, having an increased amplicon size range.
Since DesignStudio does not allow retrieval of exact
primer locations, 20 bp regions on both the 3′ and 5′ end
were considered as primer annealing sites for assays
designed by this tool. Figure 3d shows that primerXL also
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outperforms both other primer design tools with respect
to lower frequency of secondary structures in primer
annealing regions.
Conclusion
Although PCR is a cost-efficient, easy and efficient target
enrichment strategy for both next generation sequencing
as well as large scale Sanger confirmation sequencing, its
use is hampered by the lack of tools capable in designing
the large number of assays required to cover the target
of interest. Our newly developed primerXL pipeline is
an easy to use primer design tool for singleplex PCR
based targeted resequencing and has proven its value in
several projects. A one-pass primerXL design intended
for high-quality DNA typically results in amplicons cover-
ing at least 96% of the target region with very high coverage
uniformity (~ 70% within 2-fold above and 2-fold under
the mean coverage), outperforming other hybridization or
solution based target enrichment strategies [2]. Also, com-
pared to other primer design tools capable of generating
assays for targeted resequencing, primerXL scores better
when looking at target coverage (covering all splice variants
and with larger fraction on-target), percentage on-target
sequence and quality of the designed assays. PrimerXL can
be accessed at [9].
Availability and requirements
Project name: primerXL
Project home page: http://www.primerXL.org
Operating system(s): Platform independent.
Programming language(s): Perl, PHP, HTML.
License: GNU GPL.
Any restrictions to use by non-academics: licence needed.
Additional files
Additional file 1: Figure S1. Impact of assay features on sequencing
coverage in project 1. Scatter plots of the assay sequencing coverage in
function of A) the Gibbs free energy, B) the amplicon length and C) the
amplicon GC content. Cumulative percentage plots of the assay sequencing
coverage in function of D) the secondary structure content in primer
annealing sites and E) the assay specificity level. Pearson correlation values
and p values were calculated using the R functions cor() and ks.test()
(Kolmogorov-Smirnov test) respectively. (PDF 795 kb)
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Fig. 3 Targeted resequencing assay statistics. Graphical representation of the targeted resequencing assay statistics for five genes (SACS, SETX, APTX,
ANO10, CYP27A1) designed using three primer design tools (primerXL, Optimus Primer and Illumina DesignStudio): a Target coverage efficiency,
b Distribution of the amplicon sequence and percentage of amplicons harbouring SNPs (c) or secondary structures d in primer annealing sites
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Additional file 2: Figure S2. Impact of assay features on sequencing
coverage in project 3. Scatter plots of the assay sequencing coverage in
function of A) the Gibbs free energy, B) the amplicon length and C) the
amplicon GC content. Cumulative percentage plots of the assay sequencing
coverage in function of D) the secondary structure content in primer
annealing sites and E) the assay specificity level. Pearson correlation values
and p values were calculated using the R functions cor() and ks.test()
(Kolmogorov-Smirnov test) respectively. (PDF 1450 kb)
Additional file 3: Figure S3. Design performance when using amplicon
sizes optimized for FFPE samples. Barplots showing target coverage
percentages for 31 genes – totaling 242,939 nucleotides – using 80–200,
200–300 and 80–300 basepair design size ranges. (PDF 330 kb)
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